Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects With Relapsed or Refractory Multiple Myeloma

NCT05650632 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05650632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of Etentamig (ABBV-383) in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
March 21, 2023
Completion date
August 31, 2029
Enrollment
210 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma